Conducted at the Clinic for Dermatology and Dermatological Allergology
A receding hairline and premature hair loss aff ect not just men but also repre-
sent a worrisome development for women. With the onset of menopause, one
out of three or four women will notice increased hair loss, which will ultimately
lead to the thinning of hair if left untreated. Since the cause can not be remedied,
women systematically need to prevent the symptoms. Because the treatment is
used regularly, easy and safe application is very important. A liquid scalp treat-
ment product, Plantur 39 Caff eine Tonic, was tested for subjective acceptance
Twenty women between the ages of 21 and 73 were included. Th
showed signs of beginning androgenetic alopecia or diff use alopecia and com-
plained about increased daily hair loss, which had already signifi cantly reduced
the hairline and the overall hair thickness. Twelve individuals had already expe-
rienced unsatisfactory results with other products that were either sold over the
counter, exclusively in pharmacies, or were prescription drugs. Eight individu-
als had no previous product experience.
e product to be tested consisted of an active ingredient combination from
zinc salts, niacin and caff eine. Recently, caff eine was successfully tested on the
hair organ culture model in male hair roots based on its antiandrogen proper-
e caff eine complex was complemented by the addition of a soy extract
with a standardized share of phytofl avonoids such as genistein, a proven active
ingredient in phytoestrogen replacement therapy.
e application of the test product covered four months. Th
product eff ect was made with a self-assessment questionnaire and a clinically
validated HAIRDEX questionnaire to describe the quality of life.
e Caff eine Tonic was applied to the scalp in the morning (aft er hair washing)
and massaged into the scalp using the fi ngertips.
Conducted at the Clinic for Dermatology and Dermatological Allergology
Aft er four months, the post-marketing surveillance study was completed with 19
individuals; one person withdrew prematurely from the study due to lack of time.
To assess the current hair loss, a scale with fi ve degrees of severity was consul-
ted. Subjectively, 15 test subjects noticed a distinct to very strong reduction in
hair loss, which improved up to three degrees of severity in some cases. Th
individuals rated their hair loss unchanged but on a low level. Only one person
rated her hair loss worse aft er four months.
Eighteen individuals demonstrated a correspondingly high willingness to conti-
nue to use the test product. Only one person decided to refrain from continuing
e subjective self-assessment by the test subjects was complemented by
the evaluation of a clinical, standardized questionnaire on the quality of life
(HAIRDEX). Based on 48 standardized questions, the test subjects were polled
on the criteria of emotions, self-confi dence, stigmatization, symptoms and
Graphic: Subjective self-assessment on the reduction of hair loss after 4 months
e result of the evaluation was that the test subjects perceived an improvement
of their situation with regard to all criteria during the application of the Plantur 39
e criteria of emotions, symptoms and quality of life showed a
statistically signifi cant improvement.
In contrast, the criteria of stigmatization and self-confi dence showed stronger
fl uctuations regarding the degree of impact.
e Caff eine Tonic was very well tolerable. Symptoms such as scalp itch, dand-
ruff and oily scalp decreased over the course of the test.
e HAIRDEX results confi rm the high degree of satisfaction of the test sub-
jects, 95% of whom said they would like to continue using the Caff eine Tonic.
Based on the experience of the test subjects, which had largely been unsatisfac-
tory, their expectations for success or skepticism was rated relatively high. As a
result, it was a positive surprise that, despite the very short observational period
of four months, important quality of life parameters (emotions, symptoms and
e subjective assessment of daily hair loss, which can be a major cause of stress
and depression, clearly improved during the comparably short application
Conducted at the Clinic for Dermatology and Dermatological Allergology
e application of the Plantur 39 Caff eine Tonic was rated positively by a large
majority of the participants in this surveillance study. Excellent tolerability on
the scalp and the reduction of typical scalp problems such as oily scalp, scalp
itch and taut sensations also contributed to the high product acceptance.
For further information, please visit www.plantur39.com.
Expert terminology marked in green is explained in the glossary.
Curriculum Vitae August 16, 2012 Medical Licenses: Texas: J0175 DUNS #: 96-060-3116 Board Certifications: Diplomate American Board of Anesthesiology #32715 Diplomate American Board of Pain Management Certification: Certified for outpatient management of opioid dependency. Fellowship Training: Pain Management University of Texas Health Science Center University of Texas Health Science Ce
PRESS RELEASE 22 August 2013 STYLE IN THE CITY AS EYE-CATCHING RENAULT TWIZY HITS THE STREETS Renault’s stylish two-seater compact electric vehicle made its long awaited debut in Ireland today and is now available to order from dealerships. Twizy will certainly turn heads on our streets and roads with its eye-catching looks and combined with economical running costs, it’s the id
Conducted at the Clinic for Dermatology and Dermatological Allergology
A receding hairline and premature hair loss aff ect not just men but also repre-
sent a worrisome development for women. With the onset of menopause, one
out of three or four women will notice increased hair loss, which will ultimately
lead to the thinning of hair if left untreated. Since the cause can not be remedied,
women systematically need to prevent the symptoms. Because the treatment is
used regularly, easy and safe application is very important. A liquid scalp treat-
ment product, Plantur 39 Caff eine Tonic, was tested for subjective acceptance
Twenty women between the ages of 21 and 73 were included. Th
showed signs of beginning androgenetic alopecia or diff use alopecia and com-
plained about increased daily hair loss, which had already signifi cantly reduced
the hairline and the overall hair thickness. Twelve individuals had already expe-
rienced unsatisfactory results with other products that were either sold over the
counter, exclusively in pharmacies, or were prescription drugs. Eight individu-
als had no previous product experience.
Conducted at the Clinic for Dermatology and Dermatological Allergology
Aft er four months, the post-marketing surveillance study was completed with 19
individuals; one person withdrew prematurely from the study due to lack of time.